$REGN Long
This is just my observation, but not an advice.
Technical:
REGN touched its two strong trendline since 2020 and 2021.
REGN reached the 50% correction since 2020.
REGN is oversold daily and weekly.
A significant divergence is observable on daily chart.
Price touched SMA 200.
Fundamental:
P/E: 16.9x (moderate undervalue)
Since last ATH
REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea.
Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision.
Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA)
The long possibility is high from now on.
Technical:
REGN touched its two strong trendline since 2020 and 2021.
REGN reached the 50% correction since 2020.
REGN is oversold daily and weekly.
A significant divergence is observable on daily chart.
Price touched SMA 200.
Fundamental:
P/E: 16.9x (moderate undervalue)
Since last ATH
REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea. Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision.
Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA)
The long possibility is high from now on.
הערה
small correction:
Analyst sentiments: 17 buy, 7 hold, 1 sell (BoA)
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.